Menu
1 min read · estimated
APPROVED USE
What FDA approved
First-line pembrolizumab plus fluoropyrimidine and platinum chemotherapy for adults with locally advanced unresectable or metastatic HER2-negative gastric or GEJ adenocarcinoma is limited to tumors with PD-L1 CPS of at least 1.
LAMPGEN ANALYSIS
Why it matters
The update makes PD-L1 expression part of eligibility for this existing HER2-negative combination regimen.
What research teams should watch
Capture both HER2 and PD-L1 results before applying the revised first-line eligibility criteria.
PRIMARY RECORDS